Crizanlizumab was associated with a halved likelihood of priapic events among treated patients with sickle cell disease-related priapism, according to findings from a phase 2 trial. In new data from the SPARTAN trial presented at the American Society of Hematology (ASH) 2022 Annual Meeting in New Orleans last week, a team of US investigators observed that the monoclonal antibody was associated with a reduction in priapic episodes over a half-year of treatment. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more